FR3089789B1 - Production de vaccins viraux sur une lignee cellulaire aviaire - Google Patents

Production de vaccins viraux sur une lignee cellulaire aviaire Download PDF

Info

Publication number
FR3089789B1
FR3089789B1 FR1872957A FR1872957A FR3089789B1 FR 3089789 B1 FR3089789 B1 FR 3089789B1 FR 1872957 A FR1872957 A FR 1872957A FR 1872957 A FR1872957 A FR 1872957A FR 3089789 B1 FR3089789 B1 FR 3089789B1
Authority
FR
France
Prior art keywords
production
cell line
viral vaccines
avian cell
ecacc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1872957A
Other languages
English (en)
Other versions
FR3089789A1 (fr
Inventor
Manuel Rosa-Calatrava
Guy Boivin
Julia Dubois
Mario Andres Pizzorno
Olivier Terrier
Aurélien Traversier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Laval
Centre National de la Recherche Scientifique CNRS
Universite Claude Bernard Lyon 1 UCBL
Transgene SA
Institut National de la Sante et de la Recherche Medicale INSERM
Ecole Normale Superieure de Lyon
Original Assignee
Universite Laval
Centre National de la Recherche Scientifique CNRS
Universite Claude Bernard Lyon 1 UCBL
Transgene SA
Institut National de la Sante et de la Recherche Medicale INSERM
Ecole Normale Superieure de Lyon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1872957A priority Critical patent/FR3089789B1/fr
Application filed by Universite Laval, Centre National de la Recherche Scientifique CNRS, Universite Claude Bernard Lyon 1 UCBL, Transgene SA, Institut National de la Sante et de la Recherche Medicale INSERM, Ecole Normale Superieure de Lyon filed Critical Universite Laval
Priority to US17/413,228 priority patent/US20220054618A1/en
Priority to CA3123105A priority patent/CA3123105A1/fr
Priority to EP19842600.9A priority patent/EP3893928A1/fr
Priority to PCT/FR2019/053036 priority patent/WO2020120910A1/fr
Priority to JP2021534236A priority patent/JP2022514261A/ja
Priority to CN201980091860.1A priority patent/CN113490507A/zh
Priority to BR112021011362-2A priority patent/BR112021011362A2/pt
Publication of FR3089789A1 publication Critical patent/FR3089789A1/fr
Application granted granted Critical
Publication of FR3089789B1 publication Critical patent/FR3089789B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18351—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne l’utilisation de la lignée cellulaire immortalisée ECACC 09070703, déposée le 7 juillet 2009 auprès de l’European Collection of Cell Cultures (ECACC, Salisbury, Royaume Uni) sous le numéro 09070703, pour la production d’un vaccin viral constitué par une souche atténuée dérivée d’un metapneumovirus humain. Figure pour l’abrégé : NON
FR1872957A 2018-12-14 2018-12-14 Production de vaccins viraux sur une lignee cellulaire aviaire Expired - Fee Related FR3089789B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR1872957A FR3089789B1 (fr) 2018-12-14 2018-12-14 Production de vaccins viraux sur une lignee cellulaire aviaire
CA3123105A CA3123105A1 (fr) 2018-12-14 2019-12-12 Production de vaccins viraux sur une lignee cellulaire aviaire
EP19842600.9A EP3893928A1 (fr) 2018-12-14 2019-12-12 Production de vaccins viraux sur une lignee cellulaire aviaire
PCT/FR2019/053036 WO2020120910A1 (fr) 2018-12-14 2019-12-12 Production de vaccins viraux sur une lignee cellulaire aviaire
US17/413,228 US20220054618A1 (en) 2018-12-14 2019-12-12 Production of viral vaccines on an avian cell line
JP2021534236A JP2022514261A (ja) 2018-12-14 2019-12-12 トリ細胞株によるウイルスワクチンの生成
CN201980091860.1A CN113490507A (zh) 2018-12-14 2019-12-12 在禽细胞系上生产病毒疫苗
BR112021011362-2A BR112021011362A2 (pt) 2018-12-14 2019-12-12 Produção de vacinas virais em uma linha celular aviária

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1872957A FR3089789B1 (fr) 2018-12-14 2018-12-14 Production de vaccins viraux sur une lignee cellulaire aviaire

Publications (2)

Publication Number Publication Date
FR3089789A1 FR3089789A1 (fr) 2020-06-19
FR3089789B1 true FR3089789B1 (fr) 2022-05-27

Family

ID=66776438

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1872957A Expired - Fee Related FR3089789B1 (fr) 2018-12-14 2018-12-14 Production de vaccins viraux sur une lignee cellulaire aviaire

Country Status (8)

Country Link
US (1) US20220054618A1 (fr)
EP (1) EP3893928A1 (fr)
JP (1) JP2022514261A (fr)
CN (1) CN113490507A (fr)
BR (1) BR112021011362A2 (fr)
CA (1) CA3123105A1 (fr)
FR (1) FR3089789B1 (fr)
WO (1) WO2020120910A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023166079A1 (fr) 2022-03-02 2023-09-07 Vaxxel Composition vaccinale contre deux virus respiratoires

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI359868B (en) 2002-02-21 2012-03-11 Medimmune Vaccines Inc Recombinant parainflulenza virus expression system
US7704491B2 (en) * 2003-02-28 2010-04-27 The United States Of America As Represented By The Department Of Health And Human Services Recombinant human metapneumovirus and its use
CN102268413A (zh) 2006-01-05 2011-12-07 特兰斯吉恩股份有限公司 鸟类端粒酶反转录酶
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
KR101528379B1 (ko) 2007-07-03 2015-06-16 트랜스진 에스.에이. 불멸화된 조류 세포주들
WO2009062532A1 (fr) * 2007-11-16 2009-05-22 Vironovative Bv Souches de métapneumovirus atténués vivants et leur utilisation dans des formulations de vaccin et souches de métapneumovirus chimériques
FR3084079A1 (fr) * 2018-07-23 2020-01-24 Universite Claude Bernard Lyon 1 Nouvelle souche virale attenuee et son utilisation en tant que vaccin

Also Published As

Publication number Publication date
EP3893928A1 (fr) 2021-10-20
CN113490507A (zh) 2021-10-08
BR112021011362A2 (pt) 2021-08-31
FR3089789A1 (fr) 2020-06-19
US20220054618A1 (en) 2022-02-24
CA3123105A1 (fr) 2020-06-18
WO2020120910A1 (fr) 2020-06-18
JP2022514261A (ja) 2022-02-10

Similar Documents

Publication Publication Date Title
ZA202102696B (en) Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof
MX2021000193A (es) Selección de epítopos de vacunas personalizadas contra el cáncer.
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
MX2021010701A (es) Compuestos, composiciones y metodos para el tratamiento de enfermedad.
MX2022003435A (es) Desarrollo de una vacuna novedosa atenuada viva contra la peste porcina africana basada en la eliminacion del gen i177l.
MY175620A (en) Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
EA200701128A1 (ru) Рекомбинантные штаммы bcg, обладающие повышенной способностью к высвобождению из эндосомы
MX2021014525A (es) Adenovirus modificados.
EA201892233A1 (ru) Композиции и способы, связанные с иммуногенами вич-1
MX2016014099A (es) Productos de esmalte y metodos de uso.
MX2021009105A (es) Toxinas apxia, apxiia y apxiiia inactivadas.
JOP20220092A1 (ar) جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر
MX2021000066A (es) Métodos y composiciones para la preparacion de tagatosa a partir de fructosa.
PH12017500216A1 (en) Vaccine in serotype-9 fowl adenovirus recombinant vector
MX2018003036A (es) Metodo para producir celulas progenitoras renales.
MX2018008529A (es) Virus de la tilapia de tipo ortomixo.
FR3089789B1 (fr) Production de vaccins viraux sur une lignee cellulaire aviaire
MX2019004283A (es) Proceso para preparar (9e,11z)-9,11-hexadecadienal.
MX2021000949A (es) Nueva cepa de virus atenuada y su uso como una vacuna.
BR112018074277A2 (pt) vacina de alfavírus artrogênica
RU2019127739A (ru) Вакцинный штамм вируса гриппа В/60/Колорадо/2017/1 (Линия Виктория) для производства живой гриппозной интраназальной вакцины для взрослых и для детей
ZA202104747B (en) Novel trypanosomal vaccine
MX2021015643A (es) Vacuna alogénica contra el virus de inmunodeficiencia humana (vih) basada en linfocitos t para inducir la inmunidad celular y humoral.
NZ756582A (en) Immunogenic compositions against influenza
TN2014000393A1 (en) Modified marek's disease virus, and vaccines made therefrom

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20200619

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

ST Notification of lapse

Effective date: 20230808